UnitedHealth Group posted second-quarter 2026 results that blew past Wall Street expectations across every major metric, sending shares up roughly 7% in premarket trading and positioning the healthcare giant as the standout positive mover in an otherwise cautious session. Adjusted earnings per share came in at $6.38, surpassing the LSEG consensus of $4.90 by $1.46 — a margin of outperformance that analysts described as well beyond the typical variance for a company of UnitedHealth's scale. Revenue reached $112.03 billion, edging above the $110.85 billion estimate and up slightly from $111.62 billion in the prior-year quarter.
The medical benefit ratio, the measure that has been the sector's most closely watched metric for more than two years, improved to 86.7% from 89.4% in the second quarter of 2025, reflecting the impact of benefit design changes, pricing discipline, and what the company described as ongoing medical cost management. Total earnings from operations reached $8.0 billion, up sharply from $5.2 billion in the year-ago period. UnitedHealthcare, the insurance unit, generated revenues of $86.0 billion and earnings from operations of $3.9 billion, with an operating margin of 4.6%, more than double the 2.4% recorded a year earlier. The Optum healthcare services segment contributed $65.7 billion in revenue and $4.0 billion in operating profit, with 160 basis points of year-over-year margin expansion.
Management raised its full-year 2026 adjusted earnings guidance to a range of $19.50 to $20.00 per share, up from the prior outlook of greater than $18.25 per share. The new midpoint of $19.75 comfortably exceeds the analyst consensus of $18.48 and implies continued operational improvement in the second half of the year. Full-year cash flow from operations guidance was lifted to approximately $24 billion from the prior greater-than-$18 billion forecast, and the company reiterated plans to repurchase at least $5 billion in shares during 2026.
Despite the headline beat, Chief Financial Officer Wayne DeVeydt tempered enthusiasm on the earnings call. "These results are not a reflection of trend bending or coming under control, but rather our efforts to start pushing down what is already an elevated number," DeVeydt said of medical costs. He confirmed that the company continues to lose membership, projecting a loss of roughly 500,000 ACA exchange members and 1.1 million Medicare Advantage members for the full year as affordability pressures force customers off some plans. UnitedHealthcare served 48.5 million people in the quarter, down 525,000 from the prior quarter.
UnitedHealth is in the midst of a strategic restructuring aimed at simplifying operations, improving healthcare affordability, and deploying artificial intelligence across both its insurance and care delivery functions. The company said it has eliminated 30% of prior approval volume and is transitioning Optum Rx to a fully transparent, fee-based pharmacy model. It has committed $1.5 billion to AI-driven operational improvements and is rebating profits from individual ACA coverage in 2026 as part of an effort to rebuild trust following the high-profile shooting of former UnitedHealthcare CEO Brian Thompson in late 2024.
Thursday's Dow Jones futures added 17 points, or roughly 0.02%, as UNH's gain directly offset broad index pressure from chip sector weakness, given the stock's heavy weighting in the price-weighted Dow. Peers including Cigna, Humana, and CVS Health traded modestly higher in sympathy, as the medical cost improvement narrative provides some relief for an insurance sector that has been under persistent pressure. Analysts noted the Q2 beat positions UnitedHealth favorably for the balance of 2026, though the pace of membership losses remains a key watch item for the full-year revenue outlook.